- Open Access
Behavioural and morphological evidence for the involvement of glial cell activation in delta opioid receptor function: implications for the development of opioid tolerance
Molecular Painvolume 3, Article number: 7 (2007)
Previous studies have demonstrated that prolonged morphine treatment in vivo induces the translocation of delta opioid receptors (δORs) from intracellular compartments to neuronal plasma membranes and this trafficking event is correlated with an increased functional competence of the receptor. The mechanism underlying this phenomenon is unknown; however chronic morphine treatment has been shown to involve the activation and hypertrophy of spinal glial cells. In the present study we have examined whether activated glia may be associated with the enhanced δOR-mediated antinociception observed following prolonged morphine treatment. Accordingly, animals were treated with morphine with or without concomitant administration of propentofylline, an inhibitor of glial activation that was previously shown to block the development of morphine antinociceptive tolerance. The morphine regimen previously demonstrated to initiate δOR trafficking induced the activation of both astrocytes and microglia in the dorsal spinal cord as indicated by a significant increase in cell volume and cell surface area. Consistent with previous data, morphine-treated rats displayed a significant augmentation in δOR-mediated antinociception. Concomitant spinal administration of propentofylline with morphine significantly attenuated the spinal immune response as well as the morphine-induced enhancement of δOR-mediated effects. These results complement previous reports that glial activation contributes to a state of opioid analgesic tolerance, and also suggest that neuro-glial communication is likely responsible in part for the altered functional competence in δOR-mediated effects following morphine treatment.
The opioid system, comprised of multiple highly homologous receptor families and their endogenous opioid peptide ligands, is fundamental to the modulation of the sensory and affective aspects of pain . Three classes of opioid receptors (ORs) have been identified through molecular and pharmacological techniques, namely the mu (μ), delta (δ), and kappa (κ) ORs [reviewed by 2, 3]. Morphine, a classical μOR agonist with remarkable analgesic efficacy, is the current gold standard in the clinical treatment of moderate to severe pain; however, its use in the management of chronic pain may be restricted by the development of analgesic tolerance and the unwanted side effects associated with dose escalation. As such, understanding the mechanisms underlying opioid tolerance has become the primary focus of an extensive research effort with the aim of uncovering novel therapeutic strategies to treat persistent, unremitting pain.
A growing body of evidence identifies the δOR as an instrumental player in the development of morphine-induced analgesic tolerance [reviewed by 4]. Thus, concomitant administration of δOR antagonists with morphine [5–9] or antisense oligodeoxynucleotide treatment directed against the δOR  partially blocked the development of tolerance to morphine antinociceptive effects. In agreement with this data, δOR null mutant mice had a lower propensity to develop antinociceptive tolerance to morphine compared to their wild type littermates [11, 12]. The mechanism by which δOR modulates μOR analgesic tolerance is not presently known, however, complex interactions between μ and δORs are likely to be relevant in eliciting various opioid-induced physiological responses. For example, direct coupling of μ-δORs in the form of hetero-oligomers has been demonstrated in both expression systems and spinal cord tissue , which was proposed to underlie the antinociceptive synergy between μ and δOR agonists. We, and others, have also demonstrated that chronic activation of the μOR induces a translocation of δORs from intracellular compartments to neuronal plasma membranes and this phenomenon is correlated with an increase in δOR functional competence [14–18]. Taken together, the activation and translocation of δORs may represent an important intermediary step in the development of morphine tolerance; however the mechanism underlying this trafficking remains unknown.
Several studies suggest an intimate and interactive relationship between opioids and glial cells. Once regarded as mere supports cells for CNS neurons, glial cells are now recognized as performing vital and complex functions in response to physiological stressors. Indeed, spinal glial activation has been observed in a number of pathological states including Alzheimer's [19, 20] and Parkinson's  diseases, HIV-associated dementia [22–24], as well as several persistent pain syndromes [25–30]. Moreover, spinal glial cell activation has been linked to the development of opioid tolerance. Chronic morphine treatment was reported to activate microglial  and astrocytic [31, 32] cells and to increase pro-inflammatory cytokine levels  in the lumbar spinal cords of tolerant rats. Accordingly, co-administration of a glial modulatory agent with morphine attenuated the spinal immune response and inhibited the loss of morphine analgesic potency [31, 32], suggesting that spinal glia may contribute to mechanisms responsible for opioid tolerance.
In the current study, we aimed to investigate the functional relationship between δORs and glial cells following prolonged chronic morphine administration. We employed immunohistochemical techniques as well as a behavioural nociceptive paradigm to assess whether prolonged morphine treatment is associated with the activation of spinal glial, and if indeed so, whether this spinal immune response is requisite for the observed enhancement in δOR-mediated antinociception.
Prolonged morphine treatment induces spinal astrocytic and microglial hypertrophy
The effects of morphine treatment (5–15 mg/kg every 12 h; s.c.) on spinal astrocytes and microglia were assessed by fluorescent immunohistochemistry for confocal microscopy. Lumbar spinal cord segments from rats treated, or not, with morphine and/or the glial modulating drug, propentofylline (10 μg/30 μl; intrathecally [i.t.]), were processed for fluorescent detection of both GFAP and OX42, markers of astrocytes and microglia, respectively. Morphine treatment produced a significant increase in astrocytic (F3,189 = 23.79, p = 0.0015; Figure 1) and microglial (F3,101 = 8.403, p < 0.0001; Figure 1) cell volume as compared with saline-treated rats, indicating glial cell hypertrophy. Similarly, the surface areas of both astrocytic and microglial cells were significantly greater following morphine treatment as compared with saline-treated rats (F3,189 = 18.70, p = < 0.0001 for GFAP; F3,101 = 10.32, p = < 0.0001 for OX42; Table 1). Chronic intrathecal propentofylline administration effectively attenuated this morphine-induced hypertrophy, inhibiting both the increases in cell volume and in cell surface area. Propentofylline administration alone had no effect on astrocytic cell size as it produced no change in GFAP-immunoreactivity compared with controls. Interestingly, propentofylline alone significantly increased the cell volumes and surface areas of OX42-immunoreactive cells, indicating an effect on microglia which was independent of morphine treatment.
Morphine-induced enhancement in δOR-mediated antinociception is attenuated by propentofylline
The acute effects of the selective δOR agonist [D-Ala] 2- deltorphin II (DLT; 10 μg/30 μl) on thermal nociceptive thresholds in rats receiving chronic morphine, with or without the concomitant administration of propentofylline or vehicle are depicted in Figure 2. Baseline latencies were similar in all treatment groups, indicating no effect of pretreatment on normal thermal nociception (Figure 2A). Rats that received prolonged morphine treatment had significantly higher latencies at 30 minutes post-DLT injection when compared to rats pretreated with saline (Treatment F3,15 = 8.739, p < 0.001; Time F5,15 = 19.41, p < 0.001), indicating a morphine-induced enhancement in δOR-mediated analgesia. Concomitant treatment of morphine with propentofylline significantly attenuated the morphine-induced enhancement in δOR ligand effects. Animals pretreated with morphine displayed significantly greater percent maximum possible effect (% M.P.E.) values than did saline-treated animals (F3,20 = 6.700, p = 0.0026; Figure 2B). The enhancement in DLT-mediated analgesia following morphine treatment was blocked when animals were co-treated with propentofylline. These animals displayed % M.P.E.s similar to control animals, indicating no change in δOR activity. Chronic administration of propentofylline alone had no effect on the analgesic effects of DLT, yielding % M.P.E.s similar to control animals.
Opioid agonists are highly efficacious analgesics; however their clinical use is limited by the incidence of adverse effects, particularly the development of analgesic tolerance following repeated use. A growing body of evidence identifies an important role for the δOR in modulating morphine tolerance [5–10] and this phenomenon may involve the trafficking of δORs from internal stores toward the neuronal plasma membrane, thereby enhancing the effects of δOR-selective ligands [4, 14–18, 33]. The mechanism by which this contributes to morphine tolerance is unknown; however recent studies support an active role for spinal glia following chronic morphine treatment [31, 32]. In the current study, we investigated the relationship between δORs and glial activation and indeed demonstrate a functional role for spinal glia in morphine-induced changes in δOR agonist effects. Moreover, administration of a glial inhibitor effectively blocked these changes in δOR function.
The involvement of spinal glia in the modulation of morphine analgesia has been demonstrated in both preclinical [25, 27, 31, 32, 34–36] and clinical  studies. We hypothesized that the recruitment of glial cells is a gradual response to long-term morphine administration and may be detectable at time points earlier than those at which analgesic tolerance is established. We therefore assessed the spinal immune response using a 48 h morphine dosing schedule; one which has been shown to have substantive effects on δOR trafficking and function [14–16, 38]. This dosing regimen does not produce a state of tolerance ; however it may initiate mechanisms involved early in the cascade of events leading to opioid tolerance. In developing a means of assessing the three dimensional structures of GFAP- and OX42-immunoreactive cells, we observed significant increases in cell volume and surface area of fluorescent GFAP- and OX42-immunoreactive cells in the dorsal spinal cord following prolonged morphine treatment. These results are in accordance with previous studies [31, 32] illustrating the recruitment of glia in the events precipitating opioid tolerance. Morphine-induced glial hypertrophy was attenuated by co-administration with propentofylline. Interestingly, while propentofylline administration alone had no effect on astrocytes, it produced significant microglial hypertrophy in comparison with saline-treated rats. It is not clear why this occurs, since the combination of morphine and propentofylline did not show such an effect. The neuroprotective role of microglia in the CNS is well known and this cell population is very much attuned to its microenvironment, responding swiftly to even subtle physiological changes . It is possible that the localized administration of an exogenous compound into the spinal canal, in the absence of any 'pathological' events, was sufficient to produce a microglial response, although such an observation has not been reported previously . Nevertheless, additional functional studies are necessary to determine whether this propentofylline-induced increase in cell size was indeed accompanied by an inflammatory response. Despite microglial hypertrophy, however, neither baseline tail flick latencies nor deltorphin-mediated analgesia were altered following propentofylline administration alone, suggesting that this increase in microglial cell size was not functionally relevant in our study.
Activation of both glial cells and δORs appears to be important in the mechanisms of morphine tolerance, however it is unknown whether these two events are mutually exclusive or if, in fact, they represent important and related intermediary steps in the development of tolerance. Previous studies demonstrate that δORs are trafficked from internal stores toward the neuronal plasma membrane following morphine treatment, correlating with an increased functional competence of the receptor [14–16]; however it is not known if the spinal immune response observed following morphine is requisite for this δOR trafficking event. Therefore, our second series of experiments aimed to examine the functional role of spinal glia in morphine-induced changes in δOR function. Consistent with earlier reports [14, 15, 40, 41], we observed a significant augmentation in δOR-mediated effects in rats treated with morphine. This enhancement was effectively blocked by co-administration of morphine with propentofylline, demonstrating an integral role of spinal glial activation in the functional changes in δOR.
Taken together with previous reports that glial inhibition prevents the development of morphine tolerance [27, 31, 32], this study provides additional evidence for the role of δORs in opioid tolerance and suggests that glial activity may precipitate changes in the δOR, including receptor trafficking. Glial cell activity has been documented to modulate the trafficking of ionotropic channels such as AMPA receptors [42, 43]; however the current study is the first to our knowledge to suggest such a modulation of a G protein coupled receptor. The precise mechanism by which glial-modulated functional changes in δOR may occur is unclear; however two possible mechanisms include i) increased efficiency with which the receptor couples to intracellular signaling cascades, and/or ii) enhanced cell surface expression of the receptor. Future experiments will be required to investigate these possibilities.
In the present study, we demonstrate a relationship between δOR function and spinal glial activation. Indeed, prolonged administration of morphine induced the activation of astrocytic and microglial cells in the lumbar spinal cord, which correlated with enhanced antinociceptive effectiveness of a δOR agonist. Moreover, attenuation of glial activation with propentofylline, a glial inhibitor, attenuated the enhancement of δOR agonist-mediated effects. These data support an intimate relationship between glial and opioidergic function and provide insight into the mechanisms by which opioid analgesic tolerance develops.
Adult male Sprague-Dawley rats (220–300 g; Charles River, Québec, Canada), were housed in groups of two with ad libitum access to food and water, and maintained on a reverse 12/12 h light/dark cycle. All behavioural experiments were performed during the dark phase of the cycle, and animals were handled prior to experimentation in order to reduce stress-related analgesia. All experimental protocols were approved by the Queen's University Animal Care Committee, and complied with the policies and directives of the Canadian Council on Animal Care and the International Association for the Study of Pain.
Rats were separated into one of four groups receiving i) morphine and intrathecal saline, ii) morphine and intrathecal propentofylline (inhibitor of glial activation), iii) intrathecal propentofylline alone, or iv) intrathecal saline alone (control group). Morphine sulfate (MS) was administered every 12 h by subcutaneous injections of increasing doses (5, 8, 10, 15 mg/kg in saline; Sabex, Kingston General Hospital, Kingston, Ontario, Canada). This treatment protocol was previously shown to induce the trafficking of δORs from intracellular compartments to neuronal plasma membranes in cultured cortical neurons as well as in the spinal cord . Propentofylline and saline (10 μg/30 μl diluted in saline and 30 μl, respectively; Sigma, St. Louis, MO, USA) were administered by intrathecal injection via lumbar puncture between the L4 and L5 vertebrae under brief isofluorane anesthesia every 24 hours for 5 days based on drug administration protocols required to block morphine tolerance . Successful drug placement was confirmed by a vigorous tail flick upon injection. All experiments were performed 12 hours following the final morphine injection.
Double-labeling fluorescent immunohistochemistry for confocal microscopy
Rats (n = 3 per group) were deeply anesthesized with sodium pentobarbital (75 mg/kg, i.p.; MTC Pharmaceuticals, Cambridge, Ontario, Canada) and transaortically perfused with 4% paraformaldehyde (PFA) in 0.1 M phosphate buffer (PB; 500 ml, pH 7.4). The spinal cords were removed by spinal ejection and post-fixed in the above fixative for 30 minutes at room temperature and cryoprotected in 30% sucrose in 0.2 M PB for 48 hours at 4°C. Lumbar segments were isolated and cut into 40 μm transverse sections on a freezing sledge microtome and collected in 0.1 M Tris buffered saline (TBS; pH 7.4). Free-floating sections were incubated in a blocking solution containing 10% NGS, 10% BSA followed by incubation with a rabbit polyclonal antisera recognizing glial fibrillary acidic protein (GFAP; 1:2500 working dilution; DakoCytomation, Ontario, Canada) to label activated astrocytes and a mouse monoclonal antisera recognizing OX42 (1:1000 working dilution; Serotec, NC, USA) to label CD3/CDIIB receptors on activated microglia. Spinal cord sections were incubated overnight at 4°C with both primary antibodies, followed by incubation with goat anti-mouse and goat anti-rabbit secondary antibodies (both 1:200 working dilution; Molecular Probes, Invitrogen, Ontario, Canada) conjugated to Alexa 594 and Alexa 488 fluorophores, respectively. To assess non-specific labeling, control sections were processed in the absence of primary antibodies. Sections were mounted on glass slides, air-dried, and cover-slipped using Aquamount (Fisher Scientific, Ontario, Canada).
Immunoreactive cells were visualized in the deep dorsal horn using the Leica TCS SP2 multi photon confocal microscope (100 × magnification; Leica Microsystems Inc, Ontario, Canada) and images acquired and digitalized for quantitative analysis with Leica Confocal Software. Twenty-five to thirty-five serial images were captured in 0.75 μm increments throughout the z plane using identical acquisition parameters and x-y coordinates for each of 12–20 immunoreactive cells per rat for n = 3 rats per experimental group. The serial images were then stacked and reconstructed in three dimensions using Image-Pro Plus v5.0 software (MediaCybernetics, MD, USA). Total cell volume (in pixels3) and cell surface area (in pixels2) were calculated for each cell based on the three dimensional cell reconstruction. Statistical analyses were performed using Excel XP (Microsoft, Ontario, Canada) and Prism 4.01 (Graph Pad, San Diego, CA). The average volume and surface area for cells within each treatment group were calculated and expressed as means ± s.e.m. These values were compared by one-way ANOVA followed by Tukey's post-hoc multiple comparison test. P values less that 0.05 were considered significant.
Behavioural tail flick assay
The effects of a selective δOR agonist, DLT (10 μg/30 μl [i.t.]; Sigma), on thermal nociceptive responses were assessed using the hot water tail flick assay . The distal 5 cm segment of the rat's tail was immersed in noxious 52°C water, and the latency to a vigorous tail flick was measured. For n = 6 per group, three baseline latencies were measured prior to DLT injection in order to determine the normal nociceptive responses of the animals. A cut-off latency of four times the average baseline response threshold was imposed to avoid tissue damage in the event that the animal became unresponsive following DLT injection. Rats were then injected intrathecally with DLT. Thermal latencies were measured every 10 minutes following drug administration for 50 minutes. The % M.P.E. of DLT was calculated at the 30 minute time point, as this time point corresponded with the maximum analgesic effect of DLT.
% M.P.E. = (post-drug latency - baseline) ÷ (cut-off latency - baseline) × 100
The thermal latencies to respond were analyzed by two-way ANOVA followed by Bonferroni post-hoc and the transformed % M.P.E. data were analyzed by one-way ANOVA followed by Tukey's post-hoc multiple comparison test. All values are expressed as means ± s.e.m. P values less than 0.05 were considered significant.
Bovine serum albumin
central nervous system
dorsal root ganglia
glial fibrillary acidic protein
maximum possible effect
natural goat serum
Tris buffered saline
Fields HL, Basbaum AI: Central nervous system mechanisms of pain modulation. In Textbook of Pain. Edited by: Wall PD, Melzack R. Edinburgh: Churchill Livingstone; 1994:243–257.
Dhawan BN, Cesselin F, Raghubir R, Reisine T, Bradley PB, Portoghese PS, Hamon M: International Union of Pharmacology. XII. Classification of opioid receptors. Pharmacol Rev 1996, 48: 567–592.
Kieffer BL: Opioids: first lessons from knockout mice. Trends Pharmacol Sci 1999,20(1):19–26. 10.1016/S0165-6147(98)01279-6
Zhang X, Bao L, Guan J-S: Role of delivery and trafficking of δ-opioid peptide receptors in opioid analgesia and tolerance. Trends Pharmacol Sci 2006,27(6):324–329. 10.1016/j.tips.2006.04.005
Abdelhamid EE, Sultana M, Portoghese PS, Takemori AE: Selective blockage of delta opioid receptors prevents the development of morphine tolerance and dependence in mice. J Pharmacol Exp Ther 1991,258(1):299–303.
Fundytus ME, Schiller PW, Shapiro M, Weltrowska G, Coderre TJ: Attenuation of morphine tolerance and dependence with the highly selective delta-opioid receptor antagonist TIPPψ. Eur J Pharmacol 1995,286(1):105–108. 10.1016/0014-2999(95)00554-X
Wells JL, Bartlett JL, Ananthan S, Bilsky EJ: In vivo pharmacological characterization of SoRI 9409, a nonpeptidic opioid mu-agonist/delta-antagonist that produces limited antinociceptive tolerance and attenuates morphine physical dependence. J Pharmacol Exp Ther 9409,297(2):597–605.
Riba P, Ben Y, Smith AP, Furst S, Lee NM: Morphine tolerance in spinal cord is due to interaction between mu- and delta-receptors. J Pharmacol Exp Ther 2002,300(1):265–272. 10.1124/jpet.300.1.265
Roy S, Guo X, Kelschenbach J, Liu Y, Loh HH: In vivo activation of a mutant mu-opioid receptor by naltrexone produces a potent analgesic effect but no tolerance: role of mu-receptor activation and delta-receptor blockade in morphine tolerance. J Neurosci 2005,25(12):3229–3233. 10.1523/JNEUROSCI.0332-05.2005
Kest B, Lee CE, McLemore GL, Inturrisi CE: An antisense oligodeoxynucleotide to the delta opioid receptor (DOR-1) inhibits morphine tolerance and acute dependence in mice. Brain Res Bull 1996,39(3):185–188. 10.1016/0361-9230(95)02092-6
Zhu Y, King MA, Schuller AG, Nitsche JF, Reidl M, Elde RP, Unterwald E, Pasternak GW, Pintar JE: Retention of supraspinal delta-like analgesia and loss of morphine tolerance in δ opioid receptor knockout mice. Neuron 1999, 24: 243–252. 10.1016/S0896-6273(00)80836-3
Nitsche JF, Schuller AG, King MA, Zengh M, Pasternak GW, Pintar JE: Genetic dissociation of opiate tolerance and physical dependence in delta-opioid receptor-1 and preproenkephalin knock-out mice. J Neurosci 2002,22(24):10906–10913.
Gomes I, Gupta A, Filipovska J, Szeto HH, Pintar JE, Devi LA: A role for heterodimerization of mu and delta opiate receptors in enhancing morphine analgesia. Proc Natl Acad Sci USA 2004,101(14):5135–5139. 10.1073/pnas.0307601101
Cahill CM, Morinville A, Lee MC, Vincent JP, Collier B, Beaudet A: Prolonged morphine treatment targets δ opioid receptors to neuronal plasma membranes and enhances δ-mediated antinociception. J Neurosci 2001,21(19):7598–7607.
Morinville A, Cahill CM, Esdaile MJ, Aibak H, Collier B, Kieffer BL, Beaudet A: Regulation of δ-opioid receptor trafficking via μ-opioid receptor stimulation: evidence from μ-opioid receptor knock-out mice. J Neurosci 2003,23(12):4888–4898.
Morinville A, Cahill CM, Aibak H, Rymar VV, Pradhan A, Hoffert C, Mennicken F, Stroh T, Sadikot AF, O'Donnell D, Clarke PB, Collier B, Henry JL, Vincent JP, Beaudet A: Morphine-induced changes in delta opioid receptor trafficking are linked to somatosensory processing in the rat spinal cord. J Neurosci 2004,24(24):5549–5559. 10.1523/JNEUROSCI.2719-03.2004
Hack SP, Bagley EE, Chieng BC, Christie MJ: Induction of δ-opioid receptor function in the midbrain after chronic morphine treatment. J Neurosci 2005,25(12):3192–3198. 10.1523/JNEUROSCI.4585-04.2005
Ma JY, Zhao ZQ: The involvement of glia in long-term plasticity in the spinal dorsal horn of the rat. Neuroreport 2002,13(14):1781–1784. 10.1097/00001756-200210070-00017
Itagaki S, McGeer PL, Akiyama H, Zhu S, Selkoe D: Relationship of microglia and astrocytes to amyloid deposits of Alzheimer disease. J Neuroimmunol 1989, 24: 173–182. 10.1016/0165-5728(89)90115-X
Streit WJ: Microglia as neuroprotective, immunocompetent cells of the CNS. Glia 2002, 40: 133–139. 10.1002/glia.10154
Du Y, Ma Z, Lin S, Dodel RC, Gao F, Bales KR, Triarhou LC, Chernet E, Perry KW, Nelson DLG, Luecke S, Phebus LA, Bymaster FP, Paul SM: Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. PNAS 2001,98(25):14669–14674. 10.1073/pnas.251341998
Stoler MH, Eskin TA, Benn S, Angerer RC, Angerer LM: Human T-cell lymphotropic virus type III infection of the central nervous system. A preliminary in situ analysis. JAMA 1986, 256: 2360–2364. 10.1001/jama.256.17.2360
Kibayashi K, Mastri AR, Hirsch CS: Neuropathology of human immunodeficiency virus infection at different disease stages. Human Pathology 1996,27(7):637–642. 10.1016/S0046-8177(96)90391-3
Garden GA: Microglia in human immunodeficiency virus-associated neurodegeneration. Glia 2002, 40: 240–251. 10.1002/glia.10155
Raghavendra V, Rutkowski MD, DeLeo JA: The role of spinal neuroimmune activation in morphine tolerance/hyperalgesia in neuropathic and sham-operated rats. J Neurosci 2002,22(22):9980–9989.
Raghavendra V, Tanga F, DeLeo JA: Inhibition of microglial activation attenuates the development but not existing hypersensitivity in a rat model of neuropathy. J Pharmacol Exp Ther 2003, 306: 624–630. 10.1124/jpet.103.052407
Raghavendra V, Tanga F, Rutkowski MD, DeLeo JA: Anti-hyperalgesic and morphine-sparing actions of propentofylline following peripheral nerve injury in rats: mechanistic implications of spinal glia and proinflammatory cytokines. Pain 2003,104(3):655–664. 10.1016/S0304-3959(03)00138-6
Raghavendra V, Tanga FY, DeLeo JA: Complete Freunds adjuvant-induced peripheral inflammation evokes glial activation and proinflammatory cytokine expression in the CNS. Eur J Neurosci 2004, 20: 467–473. 10.1111/j.1460-9568.2004.03514.x
Tsuda M, Shigemoto-Mogami Y, Koizumi S, Mizokoshi A, Kohsaka S, Salter MW, Inoue K: P2X4 receptors induced in spinal microglia gate tactile allodynia after nerve injury. Nature 2003,424(6950):778–783. 10.1038/nature01786
Tsuda M, Inoue K, Salter MW: Neuropathic pain and spinal microglia: a big problem from molecules in "small" glia. Trends Neurosci 2005,28(2):101–107. 10.1016/j.tins.2004.12.002
Raghavendra V, Tanga FY, DeLeo JA: Attenuation of morphine tolerance, withdrawal-induced hyperalgesia, and associated spinal inflammatory immune responses by propentofylline in rats. Neuropsychopharmacology 2004,29(2):327–334. 10.1038/sj.npp.1300315
Song P, Zhao Z-Q: The involvement of glial cells in the development of morphine tolerance. Neurosci Res 2001, 39: 281–286. 10.1016/S0168-0102(00)00226-1
Cahill CM, Holdridge SV, Morinville A: Trafficking of delta-opioid receptors and other G-protein-coupled receptors: implications for pain and analgesia. Trends Pharmacol Sci 2007,28(1):23–31. 10.1016/j.tips.2006.11.003
Narita M, Suzuki M, Narita M, Yajima Y, Suzuki R, Shioda S, Suzuki T: Neuronal protein kinase C-dependent proliferation and hypertrophy of spinal cord astrocytes following repeated in vivo administration of morphine [abstract]. Eur J Neurosci 2004,19(2):479–484. 10.1111/j.0953-816X.2003.03119.x
Lazriev IL, Kiknadze GI, Kutateladze II, Nebieridze MI: Effect of morphine on the number and branching of astrocytes in various regions of rat brain. Bull Exp Biol Med 2001,131(3):248–250. 10.1023/A:1017699315355
Johnston IN, Westbrook RF: Inhibition of morphine analgesia by LPS: role of opioid and NMDA receptors and spinal glia. Behav Brain Res 2005,156(1):75–83. 10.1016/j.bbr.2004.05.006
Lu C-H, Chao P-C, Borel CO, Yang C-P, Yeh C-C, Wong C-S, Wu C-T: Preincisional intravenous pentoxifylline attenuating perioperative cytokine response, reducing morphine consumption, and improving recovery of bowel functions in patients undergoing colorectal cancer surgery. Anesth Analg 2004, 99: 1465–1471. 10.1213/01.ANE.0000132974.32249.C8
Lucido AL, Morinville A, Gendron L, Stroh T, Beaudet A: Prolonged morphine treatment selectively increases membrane recruitment of δ-opioid receptors in mouse basal ganglia. J Mol Neurosci 2005,25(3):207–214. 10.1385/JMN:25:3:207
Kreutzberg GW: Microglia: a sensor for pathological events in the CNS. Trends Neurol Sci 1996,19(8):312–318. 10.1016/0166-2236(96)10049-7
Gendron L, Lucido AL, Mennicken F, O'Donnell D, Vincent J-P, Stroh T, Beaudet A: Morphine and pain-related stimuli enhance cell surface availability of somatic δ-opioid receptors in rat dorsal root ganglia. J Neurosci 2006,26(3):953–962. 10.1523/JNEUROSCI.3598-05.2006
Melchiorri P, Maritati M, Negri L, Erspamer V: Long-term sensitization to the activation of cerebral delta-opioid receptors by the deltorphin Tyr-D-Ala-Phe-Glu-Val-Val-Gly-NH2 in rats exposed to morphine. Proc Natl Acad Sci USA 1992,89(9):3696–3700. 10.1073/pnas.89.9.3696
Leonoudakis D, Braithwaite SP, Beattie MS, Beattie EC: TNFα-induced AMPA-receptor trafficking in CNS neurons; relevance to exitotoxicity? Neuron Glia Biol 2004,1(3):263–273. 10.1017/S1740925X05000608
Stellwagen D, Malenka RC: Synaptic scaling mediated by glial TNF-α. Nature 2006, 440: 1054–1059. 10.1038/nature04671
This work was supported by grants from the Canadian Institutes of Health Research (CIHR), the JP Bickell Foundation, Harry Botterell Foundation, and Canadian Foundation for Innovation and Ontario Innovation Trust awarded to CMC. SVH was funded by a fellowship from Queen's University. CMC is a Canada Research Chair in chronic pain. The authors would like to extend their gratitude to Lihua Xue, James Jeong, Matthew Gordon, and Jeffrey Mewburn for technical assistance.
The author(s) declare that they have no competing interests.
SVH: project conception and design; data analysis and interpretation; writing, editing, revision of manuscript
SAA: major data collection; data analysis; editing, revision of manuscript
AMWT: preliminary data collection; data analysis
CMC: project conception and design; data interpretation; editing, revision of manuscript
*All authors read and approved the final manuscript